Drug Insights

Is Anifrolumab approved by the FDA?

16 July 2024
2 min read

Yes, Anifrolumab is FDA approved. The U.S. Food and Drug Administration (FDA) approved Anifrolumab for the treatment of moderate to severe systemic lupus erythematosus (SLE) in adults on July 30, 2021. This approval provides a new option for patients with SLE who are already receiving standard treatment.

Uses and Benefits

Anifrolumab is specifically used to treat adults with moderate to severe systemic lupus erythematosus (SLE). It is designed to be used in conjunction with standard SLE treatments to help manage the symptoms of this autoimmune disease.

Administration and Dosage

Anifrolumab is administered as follows:

  • Dosage Form: Intravenous solution (300 mg/2 mL)
  • Usual Adult Dose: 300 mg IV over 30 minutes every 4 weeks
  • Administration: Given by a healthcare provider, the medication is infused slowly over 30 minutes.

Side Effects

While Anifrolumab is effective, it can cause side effects. Common side effects include:

  • Shingles
  • Cough or trouble breathing
  • Cold symptoms (stuffy nose, sneezing, sore throat)
  • Headache, tiredness, dizziness, or nausea

Serious side effects that require immediate medical attention include:

  • Allergic reactions (hives, lightheadedness, difficulty breathing, swelling of face or throat)
  • Increased susceptibility to infections (fever, chills, muscle aches, painful skin sores, painful urination, diarrhea, stomach pain, cough, shortness of breath)
  • Symptoms of herpes zoster (shingles)

Precautions

Before starting treatment with Anifrolumab, consider the following precautions:

  • Allergies: Do not use Anifrolumab if allergic to it.
  • Infections and Medical Conditions: Inform your doctor about any active or chronic infections, cancer, or previous treatments with biologics or monoclonal antibodies.
  • Vaccinations: Ensure all vaccines are up-to-date before starting Anifrolumab. Avoid live vaccines during treatment.
  • Pregnancy and Breastfeeding: Discuss with your doctor if you are pregnant, planning to become pregnant, or breastfeeding. The benefits of treating SLE during pregnancy may outweigh potential risks.

Conclusion

Anifrolumab offers a new treatment option for adults with moderate to severe systemic lupus erythematosus (SLE). It is essential to follow the prescribed administration guidelines and take necessary precautions to minimize side effects and ensure effective treatment. Always consult with a healthcare provider for personalized medical advice and treatment plans.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Satellos Submits Regulatory Filing to Begin Phase 1 Trial for SAT-3247
Latest Hotspot
3 min read
Satellos Submits Regulatory Filing to Begin Phase 1 Trial for SAT-3247
16 July 2024
This submission seeks regulatory approval through the Therapeutic Goods Administration (TGA)’s Clinical Trial Notification scheme to initiate a first-in-human Phase 1 clinical trial for SAT-3247.
Read →
Is Twyneo approved by the FDA?
Drug Insights
3 min read
Is Twyneo approved by the FDA?
16 July 2024
The U.S. Food and Drug Administration (FDA) approved Twyneo for use in the treatment of acne vulgaris on July 26, 2021.
Read →
Context Therapeutics Acquires Phase 1-ready T Cell Engager CT-95
Latest Hotspot
3 min read
Context Therapeutics Acquires Phase 1-ready T Cell Engager CT-95
16 July 2024
Context Therapeutics Inc. has publicized the acquisition of CT-95, previously the property of Link Immunotherapeutics, Inc.
Read →
Is Belumosudil approved by the FDA?
Drug Insights
3 min read
Is Belumosudil approved by the FDA?
16 July 2024
The U.S. Food and Drug Administration (FDA) approved belumosudil on July 16, 2021.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.